Leslie Velka Gautam - 08 May 2025 Form 3 Insider Report for Entera Bio Ltd. (ENTX)

Role
Chief Business Officer
Signature
/s/ Dana Yaacov-Garbeli, Attorney-in-fact
Issuer symbol
ENTX
Transactions as of
08 May 2025
Net transactions value
$0
Form type
3
Filing time
20 May 2025, 16:30:18 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gautam Leslie Velka Chief Business Officer KIRYAT HADASSAH, MINRAV BUILDING,, 5TH FLOOR, JERUSALEM, ISRAEL /s/ Dana Yaacov-Garbeli, Attorney-in-fact 20 May 2025 0002069142

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ENTX Stock Option (right to buy) 08 May 2025 Ordinary Shares, par value NIS 0.0000769 per share 60,000 $2.28 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options vest over a three-year period that commenced on April 28 2025, with one-third (1/3) of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

Remarks:

See Exhibit 24.1 - Power of Attorney